Patents by Inventor Jacob J. Sprague
Jacob J. Sprague has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346799Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 12, 2023Publication date: November 2, 2023Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744835Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11744836Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: July 30, 2021Date of Patent: September 5, 2023Assignee: Liquidia Technologies, Inc.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11712442Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: November 25, 2020Date of Patent: August 1, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 11660304Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: April 13, 2022Date of Patent: May 30, 2023Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20220257608Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: April 13, 2022Publication date: August 18, 2022Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210353640Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210353641Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20210315915Abstract: Disclosed are inhalable antiviral pharmaceutical compositions of ribavirin, methods of producing the same, and the use of such compositions in the treatment of virally associated respiratory infections, and associated diseases and conditions.Type: ApplicationFiled: November 18, 2016Publication date: October 14, 2021Inventors: Philip Charles DELL'ORCO, Brian T FARRER, Zhi HONG, Christopher D ROBERTS, John Robert SAVAGE, Jacob J SPRAGUE, Yongcai WANG
-
Publication number: 20210077504Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Patent number: 10898494Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: GrantFiled: May 5, 2017Date of Patent: January 26, 2021Assignee: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20190209538Abstract: A composition to induce analgesia includes a plurality of particles, each particle of the plurality having 40-60 wt % amino amide anesthetic or a pharmaceutically acceptable salt, hydrate, or solvate thereof and 60-40 wt % PLGA polymer including 48:52 to 52:48 molar ratio D,L lactide:glycolide and an inherent viscosity of about 0.16 to 0.24 dL/g at 0.1% w/v in chloroform at 25° C. Each particle includes a non-spherical shape less than 100 ???? in a broadest dimension, and having a volume of about 13,500 cubic micrometers. The amino amide anesthetic is crystalline and includes 50-70% crystalline form I and 30-50% crystalline form II.Type: ApplicationFiled: May 5, 2017Publication date: July 11, 2019Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: John Robert Savage, Jacob J. Sprague, Ashley Galloway, Geoffrey Hird, Marquita Nicole Lilly, Akihisa Nonoyama, Edward Graham Randles, Benjamin Maynor
-
Publication number: 20190151332Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.Type: ApplicationFiled: May 5, 2017Publication date: May 23, 2019Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
-
Publication number: 20150325329Abstract: A plurality of nanoparticles, a structure assembled therefrom, a method of forming the structure, including a plurality of particles where each particle of the plurality of particles is configured with a substantially predetermined shape and a largest dimension less than about 100 micrometers, and where each particle of the plurality of particles includes an opening through the particle.Type: ApplicationFiled: July 21, 2015Publication date: November 12, 2015Applicant: LIQUIDIA TECHNOLOGIES, INC.Inventors: Joseph M. Desimone, Robert Lyon Henn, Jacob J. Sprague